MARKET

PHAT

PHAT

Phathom Pharmaceuticals, Inc.
NASDAQ
8.55
-0.02
-0.23%
Opening 15:01 08/11 EDT
OPEN
8.61
PREV CLOSE
8.57
HIGH
8.82
LOW
8.54
VOLUME
1.25M
TURNOVER
--
52 WEEK HIGH
18.31
52 WEEK LOW
8.21
MARKET CAP
691.70M
P/E (TTM)
-6.7064
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PHAT last week (0803-0807)?
Weekly Report · 1d ago
Weekly Report: what happened at PHAT last week (0727-0731)?
Weekly Report · 08/03 09:43
PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)
Barchart · 08/03 09:07
Phathom Pharmaceuticals (PHAT) Stock Slides Despite Cash Profit Breakthrough
Simply Wall St · 07/31 23:28
Phathom Pharmaceuticals Price Target Cut to $22.00/Share From $25.00 by Guggenheim
Dow Jones · 07/31 14:22
Phathom Pharmaceuticals Is Maintained at Buy by Guggenheim
Dow Jones · 07/31 14:22
Guggenheim Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22
Benzinga · 07/31 14:12
Phathom Pharmaceuticals price target lowered to $20 from $22 at Craig-Hallum
TipRanks · 07/31 13:31
More
About PHAT
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of novel treatments for gastrointestinal diseases. It has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the United States (U.S.), Europe and Canada. PCABs are a novel class of molecules that block acid secretion in the stomach. The Company markets vonoprazan in the U.S. as VOQUEZNA (vonoprazan) tablets for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (Non-Erosive GERD) in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults.

Webull offers Phathom Pharmaceuticals Inc stock information, including NASDAQ: PHAT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHAT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PHAT stock methods without spending real money on the virtual paper trading platform.